Science
MFDS approves trial plan for 296 participants Expands development beyond ulcerative colitis and Crohn’s disease

Celltrion has received approval for a South Korean Phase 3 trial plan to expand the indications for its autoimmune disease treatment Zymfentra to include rheumatoid arthritis.
Celltrion disclosed through the Data Analysis, Retrieval and Transfer System (DART) on the 14th that the Ministry of Food and Drug Safety (MFDS) had approved the South Korean Phase 3 trial plan for CT-P13 SC (Zymfentra). The application was submitted on July 24, 2026.
The trial will include 296 patients with moderate to severe active rheumatoid arthritis. The treatment period is 52 weeks, and the study is designed as a randomized, placebo-controlled, double-blind, parallel-group trial.
The trial aims to demonstrate that CT-P13 SC is superior to placebo based on the ACR50 response rate at week 12.
Zymfentra is the subcutaneous formulation of the infliximab biosimilar Remsima IV. It was developed to improve convenience for patients receiving treatment and received marketing authorization in the United States, Europe and other regions after completing Phase 3 trials in adults with ulcerative colitis and Crohn’s disease.
The company said it expects the Phase 3 rheumatoid arthritis trial to provide treatment opportunities to more patients in addition to those with the existing indications.
Celltrion also added an investment caution, noting that the statistical probability of a clinical trial drug ultimately receiving marketing authorization is about 10% and that it may change or abandon its commercialization plans if results during clinical development fall short of expectations.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Blocking Disease Proteins With ‘Molecular Gates’ … Gate Bioscience Prepares to Enter the Clinic

Rezolute Meets Phase 3 Goal in Tumor Hyperinsulinism, Shares Rise Ahead of FDA Meeting

Regeneron’s POTS drug succeeds in Phase 2; Phase 3 to begin in first half of next year

Egene Receives Approval to Amend Phase 2/3 Trial of Quadrivalent Meningococcal Vaccine

GC Biopharma Develops Korea’s First Generative AI Drug Safety Monitoring Software, Focused on Preventing Missed Cases

Daewoong Pharmaceutical Wins Phase 1 Approval for Drug to Regenerate Intestinal Mucosa: “Beyond Immunosuppression”